C12N2506/28

Realistic Humanized Model of Disease Matrix Environment for Evaluation of Therapeutic Reversal or Cell Fate
20180298344 · 2018-10-18 ·

The present invention relates to tunable hydrogels generated by selecting an amount of polymer and cross-linker such that the resulting hydrogel when covalently linked to an extracellular matrix (ECM) provides a biomimetic three-dimensional environment.

Mesenchymal stromal cells and uses related thereto

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

INDUCTION OF PLURIPOTENT CELLS
20180163181 · 2018-06-14 ·

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

INDUCTION OF ARTERIAL-TYPE OF HEMOGENIC ENDOTHELIUM (AHE) AND ENHANCEMENT OF T CELL PRODUCTION FROM PSCS THROUGH OVEREXPRESSION OF ETS FACTORS OR MODULATING MAPK/ERK SIGNALLING PATHWAYS
20180142207 · 2018-05-24 ·

The present invention is a method of creating a population of hemogenic endothelial cells with arterial specification and enhanced T cell potential. In one embodiment, the method uses ETS transgene induction at the mesodermal stage of differentiation. In another embodiment, the method activates ERK and NOTCH signaling at the mesodermal stage of differentiation.

Cellular substrate for nuclear reprogramming

This invention relates to the use of late out-growth endothelial progenitor cells (L-EPCs) as a cellular substrate for the generation of Induced pluripotent stem cells (iPSCs). This may be useful in the production of patient-specific tissues for disease modelling, drug and toxicology screening, tissue replacement and delivery of gene therapy.

CELL POWDER TYPE CULTURED MEAT AND ITS MANUFACTURING METHOD

The present disclosure is directed to providing a method for preparing powdered cultured meat, which can increase the efficiency of cell differentiation and the protein content of cultured meat with economic feasibility and to providing powdered cultured meat with high physicochemical stability and transportability and a food composition containing the same. The powdered cultured meat has a flavor similar to that of real meat, and can be highly utilized as a high-protein food in a variety of food compositions or processed foods.

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Induction of pluripotent cells

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

Induction of pluripotent cells

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.